Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What's new?

World Journal of Gastroenterology

Volumn 13, Issue 44, 2007, Pages 5877-5887

  Ponz Sarvise M ^a   Rodriguez J ^a   Viudez, A ^a   Chopitea, A ^a   Calvo, A ^a   Garcia Foncillas J ^a   Gil Bazo, Ignacio ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Cetuximab; Epidermal growth factor receptor inhibitors; Erlotinib; Gefitinib; Metastatic colorectal cancer; Monoclonal antibodies; Panitumumab; Tyrosine kinase inhibitors

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; HKI 272; IRINOTECAN; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY HR3; MONOCLONAL ANTIBODY ICR62; OXALIPLATIN; PANITUMUMAB; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACNE; ALLERGIC REACTION; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; COLON TUMOR; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC POLYMORPHISM; HEAD AND NECK CANCER; HUMAN; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; HYPOMAGNESEMIA; KIDNEY FAILURE; KIDNEY TUMOR; LETHARGY; LEUKOPENIA; LIVER METASTASIS; LUNG CANCER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHARMACOGENETICS; QUALITY OF LIFE; RECEPTOR AFFINITY; REVIEW; SALVAGE THERAPY; SEPSIS; SKIN TOXICITY; SOLID TUMOR; STOMACH TUMOR; SURVIVAL TIME;

EID: 36349032344     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i44.5877     Document Type: Review

References (100)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No 5 IARC, Lyon, France (2001)
2. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354
3. van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994; 10: 251-337
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137
5. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-516
6. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc) 2003; 39 Suppl C: 1-16
7. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-1940
8. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5: 257-265
9. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8: 994-1003
10. Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksa H, Needl MA. LoBuglio: Cetuximab (IMC-C225) Plus Irinotecan (CPT-11) is Active in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses Epidermal Growth Factor Receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: 7 (Abstract)
11. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208
12. Au H, Karapetis C, Jonker D, O'Callaghan C, Kennecke H, Shapiro J, Tu D, Wierzbicki R, Zalcberg J, Moore M. Quality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol 2007; 25: 4002
13. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345
14. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aranda Aguilar E, Aapro M, Van Den Berg N, Eggleton S, Siena S. MABEL--A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. J Clin Oncol 2006; 24: 3549
15. Zhang W, Yang D, Capanu M, Hollywood E, Lue-Yat M, Borucka E, Azuma M, Gordon M, Saltz L, Lenz H. Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol 2007; 25: 4128
16. Azuma M, Yang D, Carpanu M, Hollywood E, Lue-Yat M, Zhang W, Danenberg KD, Danenberg PV, Saltz L, Lenz H. Molecular markers associated with response and clinical outcome to cetuximab/bevacizumab/ irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (BOND2). J Clin Oncol 2007; 25: 4113
17. Prewett MC, Hooper AT, Bassi R. Proc National Cancer Institute/ American Association for Cancer Research/European Organization for Research and Treatment of Cancer Meeting 2005: 143 (Abstract)
18. Souglakos J, Kalykaki A, Vamvakas L, Androulakis N, Kalbakis K, Agelaki S, Vardakis N, Tzardi M, Kotsakis AP, Gioulbasanis J, Tsetis D, Sfakiotaki G, Chatzidaki D, Mavroudis D, Georgoulias V. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 2007; 18: 305-310
19. Eng C, Maurel J, Scheithauer W, Wong L, Lutz M, Middleton G, Stoller R, Zubel A, Lu H, Sobrero AF. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. J Clin Oncol 2007; 25: 4003
20. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-4921
21. Andre T, Tabernero J, Van Cutsem E., Diaz-Rubio E, Cervantes A, Humblet Y, Van Laethem J, Soulié P, Zubel A, De Gramont A. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FOLFOX4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR) Final Results. ASCO Gastrointestinal 2007: 334 (Abstract)
22. Rosenberg AH, Loehrer PJ, Needle MN, Waksal H, Hollywood E, Ramos L, Saltz LB. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002; 21: 536
23. Folprecht G, Lutz MP, Seufferlein T, Schoeffski P, Nolting A, Pollert P, Koehne CH. Cetuximab and irinotecan/5-FU/FA (AIO) as first line treatment in metastatic colorectal cancer (mCRC): Final results and pharmacokinetic data of a phase I/IIa study. J Clin Oncol 2005; 23: 3640
24. Rougier P, Raoul JL, Van Laethem JL, Peeters F, Husseini C, Brezault L, Cals JC, Vedovato M, Mueser. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. J Clin Oncol 2004, 22: 3513
25. Dakhil S, Cosgriff T, Headley D, Boccia RV, Badarinath S. Cetuximab + FOLFOX6 as first line therapy for metastatic colorectal cancer (An International Oncology Network study, I-03-002). J Clin Oncol 2006; 24: 3557
26. Van Cutsem E, Nowacki M, and Lang S. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007: 4000 (Abstract)
27. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, Zampino M, Donea S, Ludwig H, ZubeL A, Koralewski P. Cetuximab plus 5-FU/ FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol 2007; 25: 4035
28. Maughan T. on behalf of the COIN Trial Management Group and Investigators: Cetuximab (C), oxaliplatin (Ox) and fluoropyrimidine (Fp): Toxicity during the first 12 weeks of treatment for the first 804 patients entered into the MRC COIN (CRIO) trial. J Clin Oncol 2007; 25: 4070
29. Hecht JR, Patnaik A, Malik I, Venook A, Berlin J, Croghan G, Wiens BL, Visonneau S, Jerian S, Meropol NJ. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. J Clin Oncol 2004; 22 Suppl 14S: 3511
30. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664
31. Mitchell EP, Hecht JR, Baranda J, Malik I, Richards D, Reiner M, Stout S, Amado RG. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis. J Clin Oncol 2007; 25: 4082
32. Berlin J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, Yang L, Amado RG, Hecht JR. Panitumumab with irinotecan/leucovorin/ 5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007; 6: 427-432
33. Peeters M, Van Cutsem E, Berlin J, Hecht J, Ruiz R, Navale L, Amado R, Meropol NJ. Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials. J Clin Oncol 2007; 25: (Meeting Abstracts)4138
34. Humblet Y, Peeters M, Siena S, Hendlisz A, Neyns B, Sobrero A, Wolf M, Woolley M, Amado R, Van Cutsem E. Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab). J Clin Oncol 2007; 25: 4038
35. Berlin J, Van Cutsem E, Peeters M, Hecht J.R, Ruiz R, Wolf M, Amado RG, Meropol NJ. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials. J Clin Oncol 2007; 25: (Meeting Abstracts) 4134
36. Rothenberg ML, Lafleur B, Washington MK, Levy DE, Morgan-Meadows SL, Ramanathan RK, Berlin JD, Benson AIB, Coffey RJ. Changes in epidermal growth factor receptor signaling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer (MCRC) treated with gefitinib (ZD1839): an Eastern Cooperative Oncology Group study. J Clin Oncol 2004; 22: (Meeting Abstracts) 3000
37. Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller WH Jr, Panasci L, Lorimer IA, Batist G, Matthews S, Douglas L, Seymour L. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 2005; 23: 165-170
38. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063
39. Magne N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, Tiffon C, Renee N, Marchetti S, Etienne MC, Milano G. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 2003; 9: 4735-4742
40. Hammond LA, Figueroa J, Schwartzber L, Ochoa L, Hidalgo M, Olivo N, Schwartz G, Smith L, Ochs J, Rowinsky EK. Feasibility and Pharmacokinetic (PK) Trial of ZD1839 (Iressa ™), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Combination with 5-Fluorouracil (5-FU) and Leucovorin (LV) in Patients with Advanced Colorectal Cancer. Proc Am Soc Clin Oncol 2001; 20: 544 (Abstract)
41. Jimeno A, Sevilla I, Gravalos C, Vega M.E, Escudero P, Torre E, Rivera F, Garcia de Paredes M.L, Colomer R, Cortes-Funes H. Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy. J Clin Oncol 2005; 23: (Meeting Abstracts) 3176
42. Chau I, Massey A, Higgins L, Botwood N, Cunningham D. Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine refractory advanced colorectal cancer (CRC). J Clin Oncol 2004; 22: (Meeting Abstracts) 3572
43. Chau I, Cunningham D, Hickish T, Massey A, Higgins L, Osborne R, Botwood N, Swaisland A. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Ann Oncol 2007; 18: 730-737
44. Veronese ML, Sun W, Giantonio B, Berlin J, Shults J, Davis L, Haller DG, O'Dwyer PJ. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer 2005; 92: 1846-1849
45. Hochhaus A, Hofheinz R, Heike M, Schlag R, Gahlemann C.G, Kubicka S. Phase I study of gefitinib in combination with FOLFIRI as 2nd-/ 3rd-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2005 (Meeting Abstracts); 23: 3674
46. Arnold D, Constantin C, Seufferlein T, Gahlemann C.G, Schmoll HJ, Kretzschmar A. Phase I study of gefitinib in combination with capecitabine and irinotecan for 2nd- and/or 3rd-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2005 (Meeting Abstracts); 23: 3691
47. Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 5613-5619
48. Zampino MG, Lorizzo K, Massacesi C. Gefitinib combined with simplified FOLFOX-6 as first-line treatment in epidermal growth factor receptor (EGFR)-positive advanced colorectal cancer. Ann Oncol 2004; 15 suppl 3: 266 (Abstract)
49. Zeuli M, Gelibter A, Nardoni C, Gamucci T, Gabriele A, Pollera CF, Di Costanzo F, Signarelli C, Ferraresi V, Cognett F. A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC). J Clin Oncol 2004 (Meeting Abstracts); 22: 3748
50. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64: 5355-5362
51. Baselga J, Schoffski P, Rojo F, Dumez H, Ramos FJ, Macarulla T, Cajal R, Kisker O, Van Oosterom A, Tabernero J. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). J Clin Oncol 2006 (Meeting Abstracts); 24: 3006
52. Niederle N, Freier W, Porschen R. Erlotinib as single agent in 2nd and 3rd line treatment in patients with metastatic colorectal cancer. results of a two-cohort multicenter phase 11 trial. Eur J Cancer 2005; 3 Suppl: 184 Poster 649
53. Townsley CA, Major P, Siu LL, Dancey J, Chen E, Pond GR, Nicklee T, Ho J, Hedley D, Tsao M, Moore MJ, Oza AM. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 2006; 94: 1136-1143
54. Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol 2006; 57: 693-702
55. Nakhoul I, Grossbard M, Blum R, Malamud S, Rodriguez T, Takhir M, Kozuch P. Phase II study of erlotinib in combination with capecitabine (XELTAR) in previously untreated metastatic colorectal cancer. Gastrointestinal ASCO 2006; 239 (Abstract)
56. Meyerhardt JA, Xhu A, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Michelini A, Vincitore M, Thomas A, Fuchs CS. Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). J Clin Oncol 2004 (Meeting Abstracts); 22: 3580
57. Delord JP, Beale P, Van Cutsem E, Clarke S, Verslype C, Bugat R, Rakhit A, Fettner S, Brennscheidt U, Feyereislova A. A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients. J Clin Oncol 2004 (Meeting Abstracts); 22: 3585
58. Messersmith WA, Phase I Trial and Biologic Study of Erlotinib Combined with FOLFOX-4 in Patients with Advanced Colorectal Cancer: Initial Results. Gastrointestinal Cancers Symposium 2005; 260 (Abstract)
59. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/ EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235-5246
60. Pippas AW, Lenz H. J, Mayer RJ, Mirtsching B, Cohn AL, Windt P, Van Cutsem E. Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy. J Clin Oncol 2005 (Meeting Abstracts); 23: 3595
61. Tejpar S, Peeters M, Humblet H, Gelderblom J, Vermorken F, Viret B, Glimelius F, Ciardiello O, Kisker, Van Cutsem E. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. J Clin Oncol 2007 (Meeting Abstract); 25: 4037
62. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810
63. Saltz L. Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity? Clin Colorectal Cancer 2005; 5 Suppl 2: S98-S100
64. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004; 22: 4772-4778
65. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004; 52: 893-901
66. Defize LH, Boonstra J, Meisenhelder J, Kruijer W, Tertoolen LG, Tilly BC, Hunter T, van Bergen en Henegouwen PM, Moolenaar WH, de Laat SW. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J Cell Biol 1989; 109: 2495-2507
67. King AC, Cuatrecasas P. Resolution of high and low affinity epidermal growth factor receptors. Inhibition of high affinity component by low temperature, cycloheximide, and phorbol esters. J Biol Chem 1982; 257: 3053-3060
68. Lax I, Bellot F, Howk R, Ullrich A, Givol D, Schlessinger J. Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules. EMBO J 1989; 8: 421-427
69. Mattoon D, Klein P, Lemmon MA, Lax I, Schlessinger J. The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Proc Natl Acad Sci USA 2004; 101: 923-928
70. Zhang W, Gordon M, Schultheis AM, Nagashima F, Azuma M, Yang D, Iqbal S, Lenz H. Two immunoglobulin G fragment C receptor polymorphisms associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab. J Clin Oncol 2006 (Meeting Abstracts); 24: 3028
71. Lenz H, Zhang W, Yang D, Carpanu E, Hollywood M, Lue-Yat M, Azuma F, Nagashima H, Chang L, Saltz L. Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Gastrointestinal Cancers Symposium 2007; 401 (Abstract)
72. Zhang W, Yun J, Press O, Gordon M, Yang Y, Mallik N, Sherrod A, lqbal S, Lenz H.J. Association of Cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225). J Clin Oncol 2004 (Meeting Abstracts); 22: 3518
73. Daneshmand M, Parolin DA, Hirte HW, Major P, Goss G, Stewart D, Batist G, Miller WH Jr, Matthews S, Seymour L, Lorimer IA. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 2003; 9: 2457-2464
74. Nagashima F, Zhang W, Gordon M, Chang H.M, Lurje G, Borucka E, Yang D, Ladner R, Rowinsky E, Lenz HJ. EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single-agent cetuximab (IMCL-0144). J Clin Oncol 2007 (Meeting Abstracts); 25: 4129
75. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286
76. Briasoulis EC, Papamichael D, Tzachanis D, Christodoulou C, Samantas E, Razis E, Papakostas P, Bakoyiannis C, Wirtz RM, Kalogeras KT. Predictive value of EGFR mRNA levels assessed by quantitative RT-PCR in primary tumors of patients treated with cetuximab for metastatic colorectal cancer. J Clin Oncol 2007 (Meeting Abstracts); 25: 4121
77. Finocchiaro G, Cappuzzo F, Janne PA, Bencardino K, Carnaghi C, Franklin WA, Roncalli M, Crino L, Santoro A, Varella-Garcia M. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol 2007 (Meeting Abstracts); 25: 4021
78. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169
79. De Roock W, De Schutter J, De Hertogh G, Janssens M, Biesmans B, Personeni N, Geboes K, Verslype C, Van Cutsem E, Tejpar S. KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetaximab. J Clin Oncol 2007 (Meeting Abstracts); 25: 4132
80. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139
81. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500
82. Moroni M, Sartore-Bianchi A, Benvenuti S, Artale S, Bardelli A, Siena S. Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. Ann Oncol 2005; 16: 1848-1849
83. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005; 11: 6650-6656
84. Jones HE, Gee JM, Barrow D, Tonge D, Holloway B, Nicholson RI. Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. Br J Cancer 2006; 95: 172-180
85. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A, Baselga J. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22: 175-184
86. Tabernero J, Rojo F, Jimenez E, Montaner I. A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc Am Soc Clin Oncol 2003; 22: 770 (Abstract)
87. Salazar R, Tabernero J, Rojo F, Jimenez E, Montaner I, Casado E, Sala G, Tillner J, Malik R, Baselga J. Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). J Clin Oncol 2004 (Meeting Abstracts); 22: 2002
88. Doi T, Ohtsu A, Saijo N, Takiuchi H, Ohhashi Y, Weber D, Tillner J, Sakata T, Sun H, Rojo F. A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody "EMD72000 (Matuzumab)" administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies. J Clin Oncol 2005 (Meeting Abstracts); 23: 3077
89. Xiong HO, Takimoto C, Rojo F, Davis D, Huang J, Abbruzzese JL, Dugan M, Thomas A, Mita A, Steward WP. A phase I study of AEE788, a multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, to determine safety, PK and PD in patients (pts) with advanced colorectal cancer (CRC) and liver metastases. J Clin Oncol 2007 (Meeting Abstracts); 25: 4065
90. Davis DW, Huang J, Liu W, Xiao L, Thomas A, Mita A, Steward W, Takimoto C, Mietlowski W, Xiong H. Pharmacodynamic analysis of receptor tyrosine kinase (RTK) activity reveals differential target inhibition in skin and tumor in a phase I study of advanced colorectal cancer patients treated with AEE788. J Clin Oncol 2007 (Meeting Abstracts); 25: 3601
91. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005; 102: 7665-7670
92. Wong KK, Fracasso PM, Bukowski RM, Munster PN, Lynch T, Abbas R, Quinn SE, Zacharchuk C, Burris H. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors. J Clin Oncol 2006 (Meeting Abstracts); 24: 3018
93. Crombet T, Torres L, Neninger E, Catala M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, Perez R, Lage A. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003; 26: 139-148
94. Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C, Gore M. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 1996; 73: 228-235
95. Versola M, Burris HA, Jones S. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J Clin Oncol 2004 (Meeting Abstracts); 22: 3047
96. Lakhai WS, Beijnen JH, Den Boer SS, Westermann AM, Versola M, Koch K, Ho P, Pandite L, Richel DJ, Schellens J. Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors. J Clin Oncol 2004 (Meeting Abstracts); 22: 2044
97. Fields AL, Rinaldi DA, Henderson CA, Germond CJ, Chu L, Brill KJ, Leopold LH, Berger MS. An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 2005 (Meeting Abstracts); 23: 3583
98. Erlichman C, Hidalgo M, Boni JP, Martins P, Quinn SE, Zacharchuk C, Amorusi P, Adjei AA, Rowinsky EK. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2006; 24: 2252-2260
99. Tejpar S, Van Cutsem E, Gamelin, Machover E, Soulie P, Ulusakarya A, Laurent S, Vauthier JM, Quinn S, and Zacharchuk C. Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). J Clin Oncol 2004 (Meeting Abstracts); 22: 3579
100. Casado E, Folprecht G, Paz-Ares L. A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic: (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC). J Clin Oncol 2004 (Meeting Abstracts); 22: 3543